Strictly private & confidential
You're one step from the confidential investor room.
A U.S. FDA prostate-pathology asset with an India execution advantage. Enter your details and accept the confidentiality agreement to continue.
  • Milestone-linked ₹30 Cr (~$3.15M) seed raise
  • Full diligence pack — regulatory, clinical, financial, legal
  • 2-minute interactive product walkthrough inside
  • Every page confidential, view-only and watermarked to you
PathMDAI, Inc. · Delaware C-Corporation Himanshu Arora, Ph.D · Founder & CEO
h.arora@pathmdai.com · www.pathmdai.com ↗
Request access · Step 1 of 2
Your details & the confidentiality agreement
Enter your information below. The agreement fills in with your details as you type — no paperwork, no printing. Accepting is a binding electronic signature.
Non-Disclosure & Confidentiality Agreement
Auto-filled · India law

This Non-Disclosure & Confidentiality Agreement (this “Agreement”) is entered into and effective as of the date of acceptance, by and between PathMDAI, Inc., a Delaware corporation (the “Company”), and [your name] (the “Recipient”), reachable at [your email].

1 · Confidential Information

The Recipient will receive the Company's investor deck, financial model, and regulatory, clinical, legal and technical materials (the “Confidential Information”), disclosed solely so the Recipient may evaluate a potential investment in the Company (the “Permitted Purpose”).

2 · Non-use & permitted recipients

The Recipient will use the Confidential Information only for the Permitted Purpose and will disclose it only to the Recipient's advisors and fund colleagues on a need-to-know basis, each bound by confidentiality obligations at least as protective as these.

3 · Independent evaluation

Nothing here restricts the Recipient from evaluating or investing in other companies, provided the Confidential Information is not used or disclosed.

4 · No offer of securities

The Confidential Information is provided for information only and does not constitute an offer to sell, or the solicitation of an offer to buy, any security.

5 · Term

The Recipient's confidentiality obligations continue for three (3) years from the date of acceptance.

6 · Governing law & disputes

This Agreement is governed by the laws of India; any dispute will be resolved by arbitration seated in India.

7 · Recipient representations & acknowledgments

The Recipient represents and acknowledges that: (a) it received access to these materials through a direct, personal communication and not as a result of any general solicitation, public advertisement, or offer made to the public; (b) it is a sophisticated party able to evaluate and bear the risks of a potential investment of this nature and, where applicable, qualifies as an accredited or otherwise eligible investor under applicable law; (c) it is reviewing these materials solely to evaluate a potential investment for its own account; (d) it understands these materials are not an offer to sell or a solicitation to buy any security, and any offering will be made only to eligible investors through definitive transaction documents; and (e) it will not forward, post, or otherwise make these materials or the access link available to the public or to anyone other than its own advisors on a need-to-know basis.

8 · Electronic acceptance

By typing your name and clicking “Agree & enter,” you confirm you are authorised to accept on behalf of the Recipient and that your typed name and click constitute a valid, binding electronic signature under applicable law, including the Information Technology Act, 2000.

⚠ Important notices — please read before entering
Not an offer. This material is for information only and is not an offer to sell or a solicitation to buy any security. Any offer will be made solely through definitive transaction documents to eligible investors.
High-risk & illiquid. Investing in an early-stage private company is speculative and illiquid; you could lose your entire investment. Comparable exits shown are context only, not a prediction.
Forward-looking. Projections, timelines and the revenue architecture are forward-looking and subject to significant uncertainty; actual results may differ materially.
Investigational product. PathMDAI software is under development and has not been cleared or approved by the FDA, CDSCO or any regulator; nothing here is a medical or diagnostic claim.
No reliance. Information is provided “as is,” without representation or warranty. Conduct your own due diligence and consult your own legal, tax and investment advisors.
Confidential. Provided under NDA for your evaluation only — do not copy, forward or distribute. Full disclosures are available inside the room.
Your signature appears here
This acceptance will be recorded as: [complete the form above] · with timestamp and IP, for the Company's records.
Verify your email · Step 2 of 2
Enter your 6-digit code
To confirm it's really you, we emailed a 6-digit code to your email. Enter it below to open the room. The code expires in 10 minutes.
Didn't get it? Check spam, or resend the code.